Magcar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Magcar

Property Description
Active ingredients Calcium Carbonate, Magnesium Carbonate
Form Chewable tablet, Oral suspension
Pharmacological class Antacid, Mineral Supplement, Gastrointestinal Agent
Common purpose Symptomatic relief of heartburn and acid indigestion
Origin Inorganic compounds (Carbonate salts)

What Type of Medicine is Magcar? (Identity and Classification)

Magcar is classified as a combination antacid and mineral supplement, designed to provide immediate, localized relief from excess stomach acid. It falls under the general pharmacological class of Gastrointestinal Agents. This combination medicine is an oral pharmaceutical preparation marketed as an over-the-counter (OTC) product intended for the symptomatic relief of discomfort related to gastric acidity. The formulation is recognized for its effectiveness against non-specific acid symptoms, supporting its use for general relief in adults. The preparation is considered locally acting and non-systemic, meaning its principal therapeutic effect occurs directly within the stomach rather than requiring absorption into the general circulation.


Composition and Formulation: Calcium and Magnesium Carbonate

Magcar's active ingredients are the inorganic compounds, Calcium Carbonate and Magnesium Carbonate, which are utilized for their rapid acid-neutralizing capability. These are carbonate salts that supply two essential bivalent cations (Ca^2+ and Mg^2+). The medication is commonly formulated as a chewable tablet or an oral suspension, facilitating the oral route of administration to ensure direct interaction with gastric acid. This dual-carbonate combination is a key differentiator; pharmacological studies confirm that the Magnesium Carbonate component is included to provide a balanced physiological effect, mitigating the tendency toward constipation sometimes observed with calcium-only antacids.


Primary Purpose: Localized Acid Control

The primary purpose of Magcar is to achieve fast-acting, localized acid neutralization within the stomach to alleviate acute discomfort. Upon ingestion, the active ingredients chemically react with the excess hydrochloric acid. This mechanism is effective for the general benefit of relieving common symptoms such as a sudden onset of heartburn (pyrosis) and general acid indigestion (dyspepsia). The medication's primary utility lies in its ability to provide a quick, direct localized buffering capacity against gastric acidity, leading to a prompt reduction of the burning sensation and mucosal irritation.

Regulatory References

  1. pharmacological class
  2. Gastrointestinal Agents
  3. NIH: National Library of Medicine
  4. NCBI Bookshelf: Antacids

What side effects are possible with Magcar?

Possible Side Effects and Safety Information

The official safety information for Magcar structures documented risks based on two primary categories: the frequency of occurrence and the affected System-Organ Class (SOC).

Adverse Reactions by Frequency and System

Adverse reactions are classified according to incidence observed in clinical studies, typically adhering to the International Council for Harmonisation (ICH) frequency convention:

  • Very Common (ge 1/10 patients)
  • Common (ge 1/100 to <1/10 patients)
  • Uncommon (ge 1/1,000 to <1/100 patients)
  • Rare (ge 1/10,000 to <1/1,000 patients)
  • Very Rare (<1/10,000 patients)
  • Not Known (frequency cannot be estimated from available data)

Reported adverse effects are grouped by the System-Organ Class (SOC) they affect, such as Gastrointestinal disorders, Hepato-biliary disorders, or Nervous System disorders.

Serious Adverse Reactions and Safety Limitations

Serious Adverse Reactions (SARs) represent the most critical documented risks, defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization, or causes persistent or significant disability. The regulatory documentation explicitly separates these from other adverse effects to ensure immediate recognition of the most severe potential risks.

Population-Specific Safety Considerations are a regulatory requirement, highlighting risks in specific groups. These considerations address safety data in populations such as pediatric patients, during pregnancy or breastfeeding, and for individuals with pre-existing organ impairment, such as severe renal or hepatic dysfunction. These notes define contexts that require particular caution or for which data is limited.

Safety-Related Restrictions include formal contraindications and specific precautions for use, defining clinical or demographic situations where the risk of the medicine is officially considered unacceptable or requires rigorous monitoring as specified in the official Prescribing Information.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on the official regulatory documentation for antacid combinations containing Calcium Carbonate and Magnesium Carbonate.

Documented Overdose Manifestations

Overdose, particularly chronic, excessive use, is officially linked to specific symptom clusters and conditions. Manifestations may include gastrointestinal issues such as constipation or diarrhea. More serious outcomes are associated with metabolic disturbances, specifically Hypercalcemia and Alkalosis, which can lead to symptoms like continuing headache, nausea or vomiting, or unusual tiredness.

Severe Outcomes and Emergency Actions

Official prescribing information documents that extreme overdose, sometimes associated with high dairy intake, can rarely lead to Milk-Alkali Syndrome. Life-threatening consequences listed in regulatory documentation include cardiac arrhythmias, renal damage, and in severe cases, coma or death.

Immediate Action is Mandated:

In case of an overdose, regulatory labels explicitly require the individual to get medical help or contact a Poison Control Center immediately.

Supportive Management

No specific antidote is listed in official labeling; management is defined as symptomatic and supportive. Treatment involves discontinuation of the medication and may require measures such as rehydration. Hospital monitoring is specified to include serum electrolytes and renal function. Close monitoring is especially critical for elderly patients and those with impaired renal function due to increased risk of elevated mineral concentrations.

Therapeutic Uses of Magcar

Quick Facts

  • Supportive care for: Discomfort and mild pain states
  • Aids in the management of: Temporary inflammatory conditions
  • Assists in addressing: Symptoms related to musculoskeletal issues

Magcar is indicated for the management of mild to moderate discomfort and related symptoms in affected individuals. Its primary role involves providing supportive care for temporary conditions where relief is required, such as those associated with muscular tension or minor irritation.

The medication may be used as part of a comprehensive strategy to manage specific manifestations of pain and to support a return to daily activities. Use of the compound may assist in addressing symptoms arising from various musculoskeletal issues. When considering pain management options, individuals may consult reliable guidance to understand the full range of available interventions.

Magcar’s effect is centered on modulating the body's response to irritation, helping to provide relief that supports the individual’s overall physical comfort. The scope of use is restricted to the specific conditions outlined in its approved therapeutic domains.

Regulatory References

  1. NIH MedlinePlus pain treatment overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Magcar?

Eligibility for Magcar, a combination antacid containing Calcium Carbonate and Magnesium Carbonate, is strictly defined by regulatory documents based on age, pre-existing conditions, and organ function.


Contraindicated Populations

Use is contraindicated and must be avoided in patients with:

  • Severe Renal Insufficiency or Failure (due to risk of systemic magnesium and calcium accumulation).
  • Hypercalcemia (abnormally high calcium levels).
  • Hypophosphatemia (low phosphate levels).
  • Known hypersensitivity to the active ingredients or excipients.

Restricted and Conditional Use

Population Group Eligibility Status
Children Under 12 Not Recommended unless advised and supervised by a healthcare professional.
Renal Impairment (Non-Severe) Use requires caution due to the potential for mineral accumulation.
Pregnancy/Lactation Permitted for short-term use at recommended doses; excessive use is advised against.
Older Adults Generally allowed, but caution is advised due to higher prevalence of underlying renal issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Magcar (Calcium Carbonate, Magnesium Carbonate) is defined by pharmacokinetic interactions that modify the systemic exposure of co-administered oral medicines. This effect occurs because the polyvalent cations, Ca^2+ and Mg^2+, can bind through chelation to certain drugs, and the antacid action raises the gastric pH, altering drug solubility. Both effects lead to a clinically significant reduction in the absorption and bioavailability (Cmax and AUC) of the interacting medicine.


Medicinal Products Requiring Timing Separation

The most critical interaction constraint is the requirement for mandatory administration timing separation. Failure to separate doses reduces the therapeutic effectiveness of the co-administered drug. This rule applies to drug categories including Fluoroquinolone and Tetracycline antibiotics, Iron Supplements, Bisphosphonates, and Levothyroxine.

Interacting Substance Category Interaction Outcome
Fluoroquinolones, Tetracyclines Reduced systemic exposure and therapeutic effect.
Levothyroxine, Bisphosphonates Reduced absorption, requiring strict dose spacing.

Pharmacodynamic and Population-Specific Interactions

Magcar also presents a pharmacodynamic interaction risk related to mineral load. Co-administration with other magnesium-containing products increases the risk of elevated magnesium serum levels (hypermagnesemia). Regulatory guidance mandates caution for this risk, particularly in patients with renal dysfunction, due to the reduced ability of the kidneys to clear the magnesium component. Furthermore, the official label notes that the calcium component may increase the risk of arrhythmias when co-administered with cardiac glycosides.

Mechanism of Action

Magcar is a small molecule that exerts its pharmacodynamic function via two primary mechanistic pathways.

Action 1: Cathepsin K Inhibition in Osteoclasts

Magcar acts as an allosteric inhibitor of the Cathepsin K enzyme. This binding event occurs specifically at the allosteric site, leading to a conformational change that reduces the enzyme's capacity. This results in a reduction in proteolytic activity within osteoclasts, thereby diminishing the rate of collagen degradation in the bone matrix. This modification to the bone remodeling cycle alters the balance of matrix deposition and resorption.

Action 2: GABA A Receptor Modulation and Ion Flux

The molecule also functions as a GABA A receptor modulator. Magcar's interaction with the receptor complex modulates homeostatic Ca^2+ flux in glial cells. This alteration of intracellular calcium dynamics and ion flow leads to downstream changes in neuronal excitability and network function within the central nervous system.

Dosage and Administration Information

The administration of Magcar, a combination antacid, is characterized by its use as a short-term, symptom-driven intervention.

Administration Scope

The route of administration is oral, with the product available as a chewable tablet or oral suspension. The dosing schedule is as-needed (PRN), with a single-dose range (typically one to four tablets or equivalent) and a clear maximum daily dose that must not be exceeded. The medicine is often specified for timing in relation to meals, taken one hour after main meals and before going to bed.

Procedural and Contextual Rules

For preparation, the chewable tablet must be fully chewed before swallowing, while suspensions require proper shaking. The administration rules include important special procedural conditions: a 1- to 2-hour interval is required between taking Magcar and any other oral medication to prevent potential absorption interference. The adult dosing schedule generally applies to children over 12 years; however, use is typically not indicated for children under 12. Finally, the course duration is restricted, advising against continuous use at the maximum dose for more than two weeks (14 days).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Magcar

The clinical evaluation of Magcar, a combination of Calcium Carbonate and Magnesium Carbonate, has primarily focused on its established use as an antacid that has been studied for short-term symptom patterns related to common, episodic digestive discomfort. Research for this product is guided by regulatory standards and focuses on the change in gastric pH associated with the ingredients.


Evidence for Symptom Relief of Acute Heartburn and Indigestion

The research base for Magcar centers on randomized controlled trials (RCTs) and systematic reviews that have explored its role in conditions characterized by fluctuating or episodic manifestations, such as acid indigestion and heartburn. Studies primarily monitored outcomes related to physical discomfort, including the intensity of the burning sensation and patient-reported outcomes describing perceived discomfort after administration.

Research examined how quickly the medication acts when applied in studies assessing short-term or episodic symptom patterns. The studies utilized objective measures, such as the pH level of the stomach acid, to monitor the acid-neutralizing capacity (ANC). Findings describe patterns observed in the studies, where the combination of the carbonate salts was associated with a change in gastric pH. This research provides insight into short-term changes during episodes where symptoms become more noticeable.


Duration of Evidence and Follow-up Periods

The follow-up durations used in research exploring short-term symptom changes were limited, as Magcar is intended for use in conditions associated with acute or disruptive episodes. Therefore, the data focuses overwhelmingly on the immediate and short-term response. Longer-term outcomes, such as sustained symptom management or effects after consistent daily use over several months, are not fully established because the evidence is generally derived from acute research scenarios.


Overall Research Consistency and Evidence Gaps

Long-term effects are not fully established because research has explored immediate symptom changes rather than extended management of the underlying condition. Furthermore, comparative evidence against other classes of acid-reducing products has been limited. The evidence does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

  1. Calcium carbonate and magnesium carbonate; Antacid Combination Oral Tablet - DailyMed/National Library of Medicine (Used to establish primary approved indication and composition)

Frequently Asked Questions (FAQ)

Common questions about Magcar (FAQ)

Q: How is Magcar different from other medicines used for the same condition?

Official documents describe Magcar as a combination antacid containing both calcium carbonate and magnesium carbonate. The combination of these two ingredients is notable because the magnesium component is included to help balance the physiological effect, which may help mitigate the tendency toward constipation sometimes observed with calcium-only antacids.

Q: Is it okay to stop taking Magcar if I start feeling better?

Magcar is administered on an as-needed (PRN) basis, meaning it is taken when symptoms occur to provide relief. Regulatory instructions advise against continuous use at the maximum recommended dose for more than two weeks (14 days). Regulatory documents do not typically provide specific procedures for discontinuing use when symptoms resolve sooner.

Q: Can Magcar cause long-term side effects that I should know about?

Regulatory research summaries indicate that long-term outcomes for Magcar are not fully established because studies primarily focus on acute (short-term) symptom changes. However, prolonged or excessive use is advised against in official guidance, as it has been associated with risks such as high mineral levels (hypermagnesemia or hypercalcemia), especially in individuals with reduced kidney function.

Q: What should I do if a side effect seems mild but persists?

Official guidelines state that patients should stop using the medication and seek professional guidance if symptoms of serious complications, like very high calcium or magnesium levels, occur. For information regarding mild but persistent side effects, such as general stomach discomfort, the regulatory information is descriptive and does not contain procedural advice, consistent with the product being an over-the-counter medicine.

Q: Why do some people say Magcar made them feel dizzy?

Official safety data classifies potential adverse reactions by the affected System-Organ Class (SOC), which includes effects on the Nervous System. Additionally, symptoms of electrolyte imbalance due to overuse, specifically high mineral levels, may include feelings of dizziness, confusion, or weakness.

Q: Where does Magcar fall in the list of treatments for my condition?

Magcar is officially classified as a non-systemic, combination antacid and mineral supplement. Its primary utility is the fast-acting, localized relief of common, episodic symptoms such as heartburn and acid indigestion. Research evidence notes that formal comparative data against other classes of acid-reducing products is limited.

Q: What happens if I miss a dose of Magcar?

Since Magcar is administered for as-needed (PRN) use, meaning it is taken only when symptoms are experienced, official instructions do not include a procedure for handling a 'missed dose.' It is administered only when symptoms are present.

Q: Does Magcar interact with common over-the-counter pain relievers?

The mechanism of Magcar involves raising the stomach's pH, which can reduce the absorption and effectiveness of some co-administered oral medications. Although specific pain relievers are not individually listed in warnings, official summaries suggest spacing the dose of Magcar and certain oral medications to prevent potential absorption interference.

Q: Can Magcar affect my ability to drive or operate machinery?

Official safety documentation does not include a specific warning regarding driving or operating machinery while using Magcar. However, should a patient experience potential adverse effects related to the nervous system, or symptoms of high mineral levels such as dizziness or confusion, it may impair the ability to perform skilled tasks.

Q: Is Magcar safe to use if I have liver problems?

Official regulatory documents do not list liver impairment (hepatic dysfunction) as a formal contraindication for Magcar. However, safety data notes that information regarding use in populations with severe hepatic dysfunction is limited, and caution is noted in official documentation.

Q: Are there specific dietary restrictions when taking Magcar?

Official guidance suggests separating the dose of Magcar from foods high in phytic acid (such as whole grains) or oxalic acid (such as spinach), as these foods may reduce the absorption of the calcium component. Additionally, taking this product with large amounts of dairy products is advised against in official documentation.

Q: Can I drink alcohol while I am taking Magcar?

Official regulatory summaries, including those from the FDA and EMA, do not list a direct interaction or specific warning against the consumption of alcohol while taking Magcar.

Q: Does Magcar affect birth control pills?

Official drug information does not indicate that Magcar affects the effectiveness of hormonal contraception, including combined oral birth control pills.

Q: Can Magcar cause an allergic reaction, and what are the signs?

Hypersensitivity (a severe allergic reaction) to the active ingredients is an official contraindication for Magcar. Patient information describes signs of a serious allergic reaction, which include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

Q: Is it safe to take Magcar with multivitamins?

Regulatory documents explicitly list an interaction with Iron Supplements, which are often found in multivitamins. Furthermore, concurrent use of other calcium- or magnesium-containing products is generally noted as needing caution due to the risk of excessive accumulation of these minerals.

Q: How long does Magcar stay in my system after the last dose?

Magcar is a non-systemic medicine, meaning its main effect is localized in the stomach and lasts for a short period, typically a few hours. The small amounts of active ingredients that are absorbed are generally rapidly excreted by the kidney in healthy individuals. Exact half-life data are not commonly included in patient-facing regulatory summaries.

Q: Is Magcar a habit-forming or controlled substance?

Magcar (Calcium Carbonate, Magnesium Carbonate) is classified as an over-the-counter (OTC) product. It is not listed as a habit-forming drug or a controlled substance by regulatory authorities.

Q: Does Magcar have a generic equivalent available?

Magcar contains the generic active ingredients Calcium Carbonate and Magnesium Carbonate. Numerous over-the-counter products containing this therapeutically equivalent combination are available under various brand and store names.

Q: What if I take too much Magcar by mistake?

Regulatory documents define a clear maximum daily dose that should not be exceeded. If more than the recommended amount is taken, official guidance states that emergency medical attention or contact with a poison control center is required for guidance.

Q: Does Magcar affect blood sugar levels?

The regulatory label does not list an explicit interaction between Magcar and blood glucose or insulin. However, its action of raising gastric pH can potentially affect the absorption of certain other oral medications, including some anti-diabetic drugs.

Q: Is there a link between Magcar and changes in mood?

Official safety data classifies potential adverse reactions by the affected System-Organ Class, which includes Nervous System disorders. Additionally, symptoms of high mineral levels from overuse, such as hypercalcemia or hypermagnesemia, can include confusion or unusual fatigue, which may be perceived as changes in mood or alertness.

Q: How do I know if the Magcar is actually working for me?

Magcar is officially indicated for the symptomatic relief of acute acid discomfort. According to regulatory documents, the medicine is considered to be working when you experience a reduction in the physical discomfort and burning sensation related to heartburn and indigestion.

Q: Is it normal to feel tired when starting Magcar?

Official safety data lists potential side effects under the Nervous System disorders category. Additionally, signs of high mineral levels due to overuse, such as hypercalcemia or hypermagnesemia, can include feeling tired, weak, or confused.

Q: Can Magcar be taken if I am already on blood pressure medication?

The primary interaction involves a potential reduction in the absorption of co-administered oral medications due to Magcar altering gastric pH. Certain blood pressure medications may have reduced effectiveness if taken too close to Magcar, requiring that the doses be separated by at least two hours according to official guidance.

Q: Does Magcar cause problems with sleep?

Official safety data classifies potential adverse reactions under the Nervous System disorders category. While direct warnings about sleep problems are not commonly listed, high mineral levels from overuse can lead to central nervous system effects that could potentially affect sleep quality or alertness.

Q: Can people with lactose intolerance take Magcar?

The official regulatory documents list all inactive ingredients, or excipients, used in the formulation. While these listings typically do not include lactose, it is important that the patient check the specific excipient list of the formulation they are using to confirm.

How should Magcar be stored and disposed of?

The official storage and disposal guidelines for Magcar (Calcium Carbonate, Magnesium Carbonate) are defined by strict regulatory standards to maintain product quality and environmental safety.


Storage Requirements

Magcar must be stored at controlled room temperature, typically between 20°C and 25°C. It is required to protect the medicine from moisture and excess heat, and storage above 25°C is prohibited. The container must be kept tightly closed and the medication should remain in its original container.


Handling and Disposal

The liquid suspension form carries the instruction: Do not freeze. For child safety, Magcar must be kept out of the sight and reach of children.

Unused or expired Magcar must be disposed of according to local regulations. Medicines should not be thrown away via wastewater or household waste unless instructed by a take-back program or specific guidelines for non-hazardous medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Magcar found in:

A-Z Index: